Search results
Results from the WOW.Com Content Network
The Drug Rebate Equalization Act of 2009 (DRE), introduced in the 111th United States Congress by Representative Bart Stupak as H.R. 904, and in the Senate by Senator Jeff Bingaman as S. 547, sought to equalize the treatment of prescription drug discounts between Medicaid managed care and Medicaid fee-for-service.
Misclassification under the Medicaid Drug Rebate Program: False Claims Act: 2010 14 (tie) 13 Trileptal: Novartis [18] $465,000,000 $390 million ($465 million with co-defendant settlements) Off-label promotion/kickbacks False Claims Act/FDCA 2008 17 14 Actiq/Gabitril/Provigil: Cephalon [19] $425,000,000 $375 million civil ($425 million with ...
Misclassification under the Medicaid Drug Rebate Program: EpiPen (epinephrine) False Claims Act: 2006 Schering-Plough [21] $435 million Off-label promotion, kickbacks, Medicare fraud Temodar, Intron A, K-Dur, Claritin RediTabs: False Claims Act, FDCA 2004 [22] Pfizer $430 million Off-label promotion Neurontin: False Claims Act, FDCA 2008 ...
As many as 3 million New Yorkers may be fraudulently reaping taxpayer-funded Medicaid and other public health insurance benefits at a potential cost of $20 billion a year, a staggering new study ...
Yet there are gaps in how the billions of taxpayer-supported funding for Medicaid programs in New York addresses maternal health needs. ... About 17% of women ages 18 to 49 on Medicaid who needed ...
It required pharmaceutical manufacturers to provide rebates for medication purchases, based on sales to Medicaid beneficiaries, as a condition of having their products covered by Medicaid. [3] The amount of the rebates paid to the states were based on a "best price" calculation that did not take into account the discounted prices that ...
Newly elected Louisiana Gov. John Bel Edwards (D) enacts the Medicaid expansion shortly after taking office. New Kentucky Gov. Matt Bevin (R) announces his plan for a conservative remake of his state’s Medicaid program, and threatens to rescind the expansion if the Obama administration doesn’t approve it. Nov. 2016
Ron Wyden stated in April 2019 that they were as “clear a middleman rip-off as you are going to find”, because they make more money when they pick a higher-priced drug over a lower-priced drug. [54] In June 2024, the New York Times released its first article in a series critiquing pharmacy benefit managers for artificially raising drug ...